Yungjin Pharm transfers Japan rights to KL1333 to Pharming Technologies

Yungjin Pharm transferred Japanese rights to KL1333 to Pharming Technologies, which now holds worldwide rights outside South Korea; the transfer includes additional upfront, milestone and royalty payments beyond the existing $3 million upfront and $54 million in milestones.